Jennifer Taubert

- Since joining Johnson & Johnson in 2005, Jennifer Taubert has led global commercial strategy for the pharmaceuticals business, served as president of internal medicine, and been company group chairman for the Americas. In 2018 she was appointed executive vice president and worldwide chairman for pharmaceuticals. - In 2023, following the spinning off of J&J’s consumer products unit, the Janssen Pharmaceutical Companies of Johnson & Johnson was rebranded and launched as Johnson & Johnson Innovative Medicine. The division saw operational growth of 7% in 2023, and contributed more than $54 billion to J&J’s net trade sales of more than $85 billion. It saw success in particular with treatments for multiple myeloma, prostate cancer, and immune-related diseases. The division made 24 acquisitions and licensing deals, deploying more than $5 billion in capital. - Taubert’s division has worked to promote diversity in clinical trials, including one aiming to help patients and providers diagnose skin psoriasis in people of color, who are currently underserved when it comes to detection and treatment of that disease.